Atacama Therapeutics, Inc. is a United States-based startup founded in 2016 by a team of experienced life science professionals. The company is dedicated to advancing a treatment for hyperhidrosis, addressing a significant unmet medical and quality of life need. Atacama's focus is on establishing proof-of-concept for TC-5214 in this indication and anticipates initiating registration trials within two years. With a recent $830.00KVenture Round investment on 07 May 2024, Atacama aims to rapidly advance its program from proof of concept to a dose-ranging study. The company's industry focus spans Biopharma, Biotechnology, and Lifestyle, and it seeks to develop a portfolio of dermatology-focused products for worldwide markets. Additionally, the team has identified opportunities for novel therapies for psoriasis and scleroderma, with plans to advance these therapies from pre-clinical to clinical development next year.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $830.00K | - | 07 May 2024 |
No recent news or press coverage available for Atacama Therapeutics, Inc..
We care about your data, and we'd love to use cookies make your experience better.
